Our law firm is currently handling lawsuits on behalf of individuals who have been injured after being treated with Xeljanz. Lawsuits against the manufacturers of Xeljanz claim that patients taking Xeljanz have an increased risk of blood clots, cancer, and death.
Xeljanz is prescribed primarily for the treatment of rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis. RA is an autoimmune disorder that leads to chronic joint inflammation. Xeljanz is used to reduce pain and swelling in the joints.
The use of Xeljanz has been associated with serious cardiovascular disease and cancer. In February 2019, and February 2021, the U.S. Food and Drug Administration alerted the public about the increased risks of blood clots and cancer based on the conclusions of clinical trials. In September 2021, the FDA advised Pfizer to include a cancer warning on its medication labels.
Patients who take Xeljanz are at an increased risk for cardiac arrest, congestive heart failure, deep vein thrombosis, pulmonary embolism, myocardial infarction (heart attack), lymphoma and other cancers (including breast, colon, lung, and prostate).
The Lake Law Firm was founded by Edward J. Lake, Esq., a personal injury lawyer for over 25 years. Our dedicated team of attorneys is committed to seeking justice on behalf of those who have suffered injury or death due to the negligence of others. Our experienced attorneys handle many different types of pharmaceutical drugs, medical devices, and other defective products. The lawyers in our firm have helped collect millions of dollars for their clients. The Lake Law Firm will advocate for you and your rights. Please contact us for a free confidential case evaluation at (888) 274-0139 or submit an inquiry on this page.
In February 2019, the FDA’s review of Xeljanz found a higher incidence of blood clots and death in patients taking a 10 mg twice daily dose of Xeljanz. This particular dosage was originally approved by the FDA only for the treatment of ulcerative colitis. For patients with RA, the approved dosage is 5 mg twice daily. The European Medicines Agency also issued a warning about exceeding the recommended dose of Xeljanz to treat RA.
In February 2021, the FDA issued a follow up alert based on the preliminary results of its clinical safety trial. In September 2021, the FDA published the results of its completed clinical trial to alert the public of an increased risk of serious heart disease, stroke, and cancer with Xeljanz as compared to other medications that are used for the treatment of arthritis and ulcerative colitis, including tumor necrosis factor inhibitors (TNF), commonly known as Humira. The trial also concluded that there was an increased risk of death even with the reduced dose of Xeljanz, contraindicating earlier reports that the most serious side effects were associated only with higher doses.